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Background: Guanylin (GN) and uroguanylin (UGN) are endogenous ligands for the 
intestinal receptor guanylate cyclase C (GC-C), an important regulator of intestinal fluid 
homeostasis. Gene expression and protein levels of GN are suppressed in inflamed intestinal 
tissue from patients with inflammatory bowel disease (IBD), but knowledge about plasma 
levels of guanylins in these conditions is sparse. We aimed to investigate the fasting plasma 
levels of the prohormones proGN and proUGN in patients with Crohn’s Disease (CD) and 
relate these to levels found in persons with other diarrheal conditions, as well as persons with 
normal bowel habits.  
Methods: Plasma from patients with CD, patients with Familial GUCY2C Diarrheal Disease 
(FGDS), diarrhea-predominant irritable bowel syndrome (IBS-D) and healthy controls (HC) 
was analyzed using ELISA assays.  
Results: Significantly lower fasting plasma levels of proguanylins were found in CD and 
FGDS patients, compared to HC. In CD patients, plasma proGN levels correlated negatively 
with Harvey Bradshaw Index and with number of stools / 24 h.   
Conclusion: Our data indicate that diarrhea may be a determinant for levels of proGN in 











The intestinal guanylate cyclase-C receptor (GC-C) and its endogenous ligands guanylin 
(GN) and uroguanylin (UGN) have gained renewed interest due to their importance for 
intestinal hydration and homeostasis [1,2], as well as their role in intestinal inflammation 
[3,4]. Expression of the genes encoding GC-C (GUCY2C) and the guanylins (GUCA2A and 
GUCA2B) are reduced in inflamed colonic tissue [3,5], and the silencing of the pathway is 
reported to normalize when the patients experience remission [3]. 
Proguanylin (proGN) and prouroguanylin (proUGN) are peptides mainly produced in the 
intestinal epithelial cells [6] and their biologically active forms, the hormones GN and UGN 
represent the C-terminal parts of the biological inactive prohormones. They are cleaved from 
the prohormones by converting enzymes upon secretion [7,8], and elicit autocrine as well as 
paracrine functions [8]. After secretion into the intestinal lumen, GN and UGN bind to the 
guanylate cyclase-C receptor (GC-C) which in turn leads to increased cellular level of cyclic-
guanosine-monophosphate (cGMP), and to phosphorylation of the cystic fibrosis 
transmembrane regulator (CFTR) resulting in increased secretion of Cl¯, bicarbonate and 
water into the lumen. GC-C activation also leads to an inhibition of the Na+/H+ exchanger 
(NHE3), resulting in reduced absorption of Na+ [1]. ProGN and proUGN are also secreted 
into the circulation, and can be measured in plasma [9,10], but detailed regulation of secretion 
of proGN and proUGN from the gut mucosa cells into blood and into the intestinal lumen is 
not well investigated in humans. 
 In 2012 our group discovered an activating GUCY2C gene mutation (c.2519G>T) in a 
Norwegian family (n=35), named familial GUCY2C diarrhea syndrome (FGDS) [11,12]. In 
persons with this mutation the GC-C receptor is hyperactive when GN and UGN are bound to 
it, which in turn leads to increased intraluminal fluid in the intestine [11]. We observed that 
affected persons in this family had chronically loose stools, median 4 per day (range 1-10). In 
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addition, we found dysmotility and increased fluid in the lumen of the small bowel in the 
FGDS patients [12,13].  
In patients with inflammatory bowel syndrome (IBD) in remission, approximately 30-40 % 
have symptoms resembling irritable bowel syndrome (IBS), and may therefore be difficult to 
separate from IBS patients [14]. IBS is a syndrome defined by long lasting, variable 
abdominal pain/discomfort that fluctuates in concert with changes in stool frequency or 
consistency. Some patients have mainly loose stools and these may be defined to have 
diarrhea predominant IBS (IBS-D)  according to specific Rome criteria [15]. The symptoms 
of FGDS patients resemble IBS-D [11]. 
Little is known about the levels of guanylins in blood in humans with diseases where diarrhea 
is a predominant symptom. Therefore, the aim of the current study was to measure plasma 
levels of proGN and proUGN in patients with CD and compare with patients with FGDS, 
IBS-D and with plasma levels in a healthy control group (HC).  
 
Subjects and Methods 
Subjects  
The majority of the CD patients were recruited from the hospital routine outpatient clinic.  
Harvey-Bradshaw Index (HBI) was recorded from all CD patients. HBI is a clinical index of 
Crohn's-disease activity composed of number of diarrhea last 24 hours, extra- intestinal 
manifestations, general condition and abdominal masses [16].  
FGDS patients were recruited into the study when the GUCY2C mutation (c.2519G >T) had 
been confirmed. Patients with diarrhea-predominant IBS (IBS-D) according to Rome II 
criteria, were recruited from a cohort of patients with post-infectious IBS during follow up 
around 5 years after the eliciting Giardia infection [17]. HCs were recruited using bulletin 
boards at Haukeland University Hospital and via a recruitment website. Participants in the HC 
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group were interviewed before inclusion in order to obtain information of their clinical status 
and to define them as healthy, without previous history of gastrointestinal disease.  
Informed consent was obtained from all participants and the study was approved by the 
Regional Committee for Medical Research Ethics, Haukeland University Hospital, 2014/222, 
2009/902, and performed in accordance with the declaration of Helsinki. 
 
Samples  
Plasma from all participants was obtained after an overnight fast. EDTA whole blood was 
centrifuged at 1800 x g, 4 °C for 10 minutes and plasma was stored in aliquots at -80 °C until 
analysis. Plasma proGN and proUGN concentrations were determined using sandwich 
enzyme-linked immunosorbent assay (ELISA) kits (BioVendor, Karasek, Czech Republic, 
Cat. No. RD191069200R and RD191046100R, respectively). The ELISAs were performed 
according to the manufacturer’s instructions. The absorbance was measured by 
SPECTRAmax microplate reader (Molecular Devices, Sunnyvale, CA, US), and 
concentrations of proGN and proUGN were calculated by the SoftMaxPro Software version 
5.4.5.000 (Molecular Devices, Sunnyvale, CA, US) using the four-parameter algorithm 
standard curve fitting. 




Descriptive data are presented as median (range). One-way ANOVA with Bonferroni 
correction for adjustment was used when comparing the plasma levels of guanylins between 
groups, otherwise Student’s t-test. For analyses of correlation, Pearson´s test was used. 
P<0.05 was considered statistically significant. Data were analysed with SPSS 22 Software 
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(Chicago, Illinois, USA) and Graph Pad Prism version 5.02 for Windows (Graph Pad 
Software Inc., La Jolla, CA, USA).   
 
Results  
Characterization of study participants 
Details of study participants are shown in Table 1. There was no significant difference 
between age and gender in the 4 groups.  
The CD patients were referred from the outpatient clinic of the Department of Medicine, 
Haukeland University Hospital, Bergen, Norway. They had suffered from CD for median 10 
years (3-30), median age at diagnosis was 19 (10-57) and median years on TNF-α-inhibitors 
were 7 (0-15). None of the patients had short bowel syndrome, 25 had received bowel 
surgery, 4 had permanent stoma, and the majority (n=25) had colonic involvement. Thirty of 
the CD patients were treated with TNF-α-inhibitors (Infliximab or Adalimumab), three were 
treated with α4β7 integrin blockade (Vedolizumab) and 2 received no medical treatment. 
Thirty-one of the CD patients were scored with HBI index, 4 had stoma and HBI could not be 
assessed. Patients with clinical inactive (HBI ≤ 4) and active (HBI>4) disease were analyzed 
separately. No CD patients tested positive for the GUCY2C mutation (c.2519G>T).  
Five of the FGDS patients had a concomitant diagnosis of CD, all in clinical remission,  
 and one currently treated with adalimumab 40 mg subcutaneously every second week.  
Four children from the FGDS family aged 3, 5, 6 and 7 years old were included.  
All IBS-D patients fulfilled the Rome II criteria for diagnosis of IBS-D 






Fasting plasma levels of guanylins  
Levels of plasma proGN were lower in all CD patients (5.1 ng/mL ± 1.6, p<0.001) as well as 
in FGDS patients (6.0 ng/mL ±1.3, p = 0.01) compared to the HC (7.8 ng/mL ± 1.9) (Figure 
1). The five patients with FGDS combined with CD did not differ in guanylin levels from the 
remaining FGDS patients, but we noted that for proguanylin they clustered at the lower end of 
the range for the group. 
Plasma proGN levels were still significantly lower compared to HC when the groups of CD 
patients with active inflammation (HBI > 4) or remission (HBI ≤ 4)   were analyzed 
separately (figure 1). No difference in plasma levels of proGN between the two CD groups 
was found (p=0.52). ProGN levels differed between IBS-D (6.7 ng/ml ± 2.0 ng/ml) and all 
CD patients (p=0.005), as well as the subgroup of CD patients with active inflammation (HBI 
> 4) (p<0.01). There were no differences between IBS-D patients compared to FGDS patients 
or to HC.  
Fasting plasma levels of proUGN showed a similar pattern, with significantly reduced levels 
in all CD patients (2.1 ng/ml ± 0.8, p<0.05), and FGDS patients (2.1 ng/ml, SD ± 0.5, p<0.05) 
compared to HC (2.6 ng/mL ±0.8). CD patients with HBI ≤ 4 (2.0 ng/mL ± 1.4) had 
significantly lower proUGN levels than HC (p<0.05). However, in CD patients with HBI >4, 
plasma proUGN levels (2.4 ng/mL ± 1) were not significantly different from those observed 
in HC. No significant differences between IBS-D and HC were found in plasma guanylins. 
There was no correlation between CRP and guanylins, or F-Calprotectin and guanylines in the 
CD patients.   
 
Number of loose stools in CD patients 
CD patients in remission (HBI ≤ 4) had median 0 stool/24 h (range 0-4), while CD with 
inflammatory activity (HBI >4) had median 6 stools /24 h (5-15) (Table 1). 
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Looking at all CD patients together we found a negative correlation between plasma proGN 
and number of loose stools/24 hours, (r = -0.463, p=0.009, figure 2) as well as a negative 
correlation between plasma proGN and HBI (r = - 0.488, p= 0.01, figure 2). This remained 
significant also when the outlier (number of loose stools 15) was removed.  
There was no similar correlation between plasma proUGN and HBI or number of loose stools, 
or between any of the plasma guanylins and calprotectin in CD patients.  
 
Discussion 
In this study, we show that fasting plasma levels of guanylins are significantly lower in 
patients with CD and FGDS compared to HC. The changes were more marked for proGN in 
CD patients as plasma proGN correlated negatively with HBI and number of stools. In FGDS 
patients, we have previously reported negative correlation between plasma proGN and stool 
consistency score (Bristol stool chart) [13]. These data taken together suggest that frequency 
and/or consistency of stools may be important determinants for fasting plasma levels of 
proGN.  
In FGDS patients, diarrhea is caused by increased secretion of Cl- through the CFTR and 
reduced reabsorption of Na+ through NHE3 [11]. In CD patients, however, diarrhea is mainly 
caused by reduced electroneutral reabsorption of Na+ through NHE3 and Cl- through the 
Cl/HCO3
- exchanger [19]. Regardless of mechanism, the net result is loss of fluid and NaCl 
into the intestinal lumen in both conditions. 
Previous studies of guanylins in patients with IBD have focused on measurements in 
intestinal tissue, and only a small number of studies have measured guanylins in plasma. In 
1995, Kuhn et al found no significant differences in circulating proGN levels between IBD 
patients (both CD and ulcerative colitis (UC)) and HC, and no correlation between plasma 
proGN and disease activity scores [20]. However, a recent proteomic study reported reduced 
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plasma proGN in CD patients compared to HC (in line with our data) as well as to UC [10]. 
The authors suggested that proGN could discriminate between CD and UC. The reason for the 
conflicting results in the literature on plasma GN in CD patients is not clear, but could be due 
to methodological issues.  
 
Active inflammation in colonic mucosa seems to lead to reduced GC-C signaling in this 
tissue, as gene expression and cellular protein content of both GC-C and guanylins are 
reduced compared to levels in HC and to non-inflamed colonic tissue in IBD patients (normal 
levels) [3,5,21]. Such reduction in guanylin formation could be reflected in a lower secretion 
of guanylins to the bloodstream, but this was not measured in the studies referred to above. 
Interestingly, our data show that CD patients with little inflammation (low HBI) compared to 
those with higher levels of inflammation (high HBI) had reduced plasma guanylin levels 
compared to HC. This may reflect additional unknown mechanisms for reduced signaling of 
guanylins in CD patients.  
 
The mechanism for diarrhea in IBS-D patients is unknown, but in this study, we found a trend 
towards lower plasma levels of both guanylins in patients with IBS-D compared to HC, 
although the differences were not statistically significant. Further studies in different defined 
subpopulations of individuals with CD, ulcerative colitis (UC) and other diarrheal disorders 
are warranted, in order to evaluate whether fasting plasma proGN may be an indicator of 
intestinal hydration, or a consequence of low grade intestinal inflammation. 
 
Plasma proUGN showed less pronounced differences between patient groups and HCs than 
proGN in this study. There was no correlation between proUGN and number of stools or HBI 
in CD patients, nor with stool consistency score in our previous study [13]. Plasma levels of 
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UGN could be more tightly regulated and is influenced by several additional factors 
compared to GN, as UGN is expressed in a wider range of tissues and  may be important for 
regulating satiety and body weight as part of the gut-brain axis [9,22]. Thus, it might be less 
interesting to further pursue the relationship between UGN and intestinal hydration compared 
to GN.  
 
In this study, we did not have information about number of stools in the FGDS group nor in 
the IBS-D group at the time of plasma sampling. However, later studies obtained from the  
same FGDS patients have shown that they all have loose stools, lower plasma proGN and 
proUGN as well as increased number of fluid- filled small bowel loops compared to HC [13].  
 
In conclusion, fasting plasma levels of guanylins, particularly proGN, were significantly 
reduced in both CD and FGDS patients compared to HC. Plasma guanylins in the IBS-D 
patients showed a trend towards lower levels.  Our data indicate intestinal fluid loss as a 
determinant of plasma guanylins, especially proGN, but call for further studies regarding 
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